|
|
|
|
|
The Niche
|
Stem Cell & Regenerative Med Newsletter
|
|
|
|
|
|
Weekly reads: Sarepta, epigenomics, FDA on eyedrops
|
|
|
|
The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had recommended against approval. Now STAT …
|
|
|
|
|
|
|
|
Trends in retractions as AI arms race on misconduct looms
|
|
|
|
There has been a big jump in paper retractions in science over the last 20 years. What's going on? How do the trends in the stem cell field compare to other fields like cancer research and more broadly? Is AI going to change the dynamic between those engaging in misconduct and those who are looking for misconduct in papers? Retractions have spiked …
|
|
|
|
|
|
